HBV infection and HCC: the 'dangerous liaisons'
- PMID: 29196438
- DOI: 10.1136/gutjnl-2017-315528
HBV infection and HCC: the 'dangerous liaisons'
Keywords: hepatitis b; hepatocellular carcinoma.
Conflict of interest statement
Competing interests: AB declares the following relationship with commercial entities developing therapeutics for HBV treatment. He collaborates and receives research support from Gilead Sciences to test the effect of HBV antigens on immune cell function. He acted as a consultant and served on the advisory boards of Gilead Sciences, MedImmune, Jansseen-Cilag, IONIS, Abivax, HUMABS BioMed. AB is also a cofounder of LION TCR pte. ltd. a biotech company developing T cell receptors for treatment of virus-related cancers and chronic viral diseases.
Comment on
-
High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.Gut. 2018 May;67(5):945-952. doi: 10.1136/gutjnl-2017-314904. Epub 2017 Oct 21. Gut. 2018. PMID: 29055908
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical